| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Triptophenolide targets the androgen receptor (AR), including wild-type AR and mutant variants AR-T877A, AR-F876L, and AR-W741C/T877A. In transactivation assays, it exhibits IC50 values of 260 nM for wild-type AR, 388 nM for AR-T877A, 480 nM for AR-F876L, and 437 nM for AR-W741C/T877A. It also inhibits NF-κB signaling, a key regulator of inflammation and immune responses.
|
|---|---|
| ln Vitro |
In vitro, Triptophenolide (5 µM) inhibits the growth of LNCaP prostate cancer cells and reduces AR levels. It acts as a pan-antagonist of androgen receptors with sub-micromolar IC50 values against both wild-type and mutant ARs in transactivation assays. It remarkably inhibits delayed-type hypersensitivity (DTH) reactions induced by DNCB and BSA and diminishes peripheral blood ANAE+ lymphocytes in rats and mice. It modulates immune cell activity and cytokine production.
|
| ln Vivo |
In vivo, Triptophenolide has demonstrated significant efficacy in preclinical studies for autoimmune diseases, cancer, and chronic inflammatory disorders. It inhibits delayed-type hypersensitivity reactions in animal models. Its ability to modulate immune cell activity and cytokine production makes it a valuable tool for investigating molecular mechanisms of inflammation and immune regulation. Further in vivo studies are warranted to fully characterize its therapeutic potential.
|
| Enzyme Assay |
In vitro receptor binding assays for Triptophenolide are conducted using transactivation assays with AR-expressing cell lines. Cells are transfected with AR constructs (wild-type or mutant) and a luciferase reporter gene driven by androgen-responsive elements. Following treatment with varying concentrations of the compound in the presence of androgen agonist, luciferase activity is measured to determine AR antagonism. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
Cellular assays for Triptophenolide are performed using prostate cancer cell lines such as LNCaP, which express AR. Cells are seeded in culture plates and treated with compound concentrations ranging from 0.1 to 50 µM for 24-72 hours. Cell viability and proliferation are assessed using MTT, CCK-8, or BrdU incorporation assays. AR protein levels are measured by Western blotting. Apoptosis is evaluated by flow cytometry using Annexin V/PI staining.
|
| Animal Protocol |
In vivo animal studies for Triptophenolide utilize rodent models of autoimmune disease, cancer, or inflammation. Tumor xenograft models with AR-positive prostate cancer cells are used to assess antitumor efficacy. DTH reaction models with DNCB or BSA sensitization are employed to evaluate immunomodulatory effects. Compound is administered orally or intraperitoneally, and endpoints include tumor volume, immune cell populations, cytokine levels, and histopathology.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Triptophenolide have not been extensively characterized. The compound has a molecular weight of 312.40 and is soluble in DMSO (62 mg/mL) and ethanol (2 mg/mL). It is practically insoluble in water. Based on its lipophilic nature, it is expected to have good membrane permeability and oral absorption. Standard PK studies in rodents would be required to determine half-life, bioavailability, and tissue distribution.
|
| Toxicity/Toxicokinetics |
Toxicological data for Triptophenolide are limited. As a natural product-derived compound, it may have a moderate safety profile. No significant acute toxicity has been reported in the available literature. The compound is designated for research use only. Standard toxicity screening would involve acute and repeated-dose studies in rodents with evaluation of clinical signs, body weight, hematology, clinical chemistry, and histopathological examination of major organs.
|
| References | |
| Additional Infomation |
(3bR,9bS)-6-hydroxy-9b-methyl-7-propyl-2-yl-3,3b,4,5,10,11-hexahydronaphtho[2,1-e]isobenzofuran-1-one is an oxosteroid. Tripterygium glycosides have been reported to be present in Tripterygium wilfordii, Tripterygium hypoglaucum, and other organisms with relevant data.
Triptophenolide (Hypolide) is a diterpenoid from Tripterygium wilfordii that acts as a pan-antagonist of wild-type and mutant androgen receptors (IC50: 260-480 nM). It inhibits NF-κB signaling, modulates immune responses, and suppresses DTH reactions. It inhibits the growth of LNCaP prostate cancer cells and reduces AR levels. It is not clinically approved and is used as a research tool for prostate cancer, autoimmune diseases, and inflammatory disorders. |
| Molecular Formula |
C₂₀H₂₄O₃
|
|---|---|
| Molecular Weight |
312.40
|
| Exact Mass |
312.172
|
| CAS # |
74285-86-2
|
| PubChem CID |
173273
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
490.0±45.0 °C at 760 mmHg
|
| Melting Point |
232-233ºC
|
| Flash Point |
202.4±21.5 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.603
|
| LogP |
3.92
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
23
|
| Complexity |
549
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC(C)C1=C(C2=C(C=C1)[C@]3(CCC4=C([C@@H]3CC2)COC4=O)C)O
|
| InChi Key |
KPXIBWGPZSPABK-FXAWDEMLSA-N
|
| InChi Code |
InChI=1S/C20H24O3/c1-11(2)12-4-6-16-14(18(12)21)5-7-17-15-10-23-19(22)13(15)8-9-20(16,17)3/h4,6,11,17,21H,5,7-10H2,1-3H3/t17-,20+/m0/s1
|
| Chemical Name |
(3bR,9bS)-6-hydroxy-9b-methyl-7-propan-2-yl-3,3b,4,5,10,11-hexahydronaphtho[2,1-e][2]benzofuran-1-one
|
| Synonyms |
(+-Triptophenolide Hypolide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~320.10 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.00 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2010 mL | 16.0051 mL | 32.0102 mL | |
| 5 mM | 0.6402 mL | 3.2010 mL | 6.4020 mL | |
| 10 mM | 0.3201 mL | 1.6005 mL | 3.2010 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
